

FORMS RELATING TO LISTING

Form F

The Growth Enterprise Market (GEM)

Company Information Sheet

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name : **Essex Bio-Technology Limited**

Stock code (ordinary shares) : **8151**

This information sheet contains certain particulars concerning the above company (the “Company”) which is listed on the Growth Enterprise Market (“GEM”) of the Stock Exchange of Hong Kong Limited (the “Exchange”). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 26th May, 2009.

A. General

Place of incorporation : Cayman Islands

Date of initial listing on GEM : 27th June, 2001

Name of Sponsor(s) : N/A

Names of directors : ***Executive Directors:***
(please distinguish the status of the directors – Executive, Non-Executive or Independent Non-Executive)
Ngiam Mia Je Patrick
Fang Haizhou
Zhong Sheng

Independent non-executive Directors:
Fung Chi Ying
Mauffrey Benoit Jean Marie
Yeow Mee Mooi

Name(s) of substantial shareholder(s) :
(as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company

Name	Number of shares held	Approximate percentage of the Company's issued share capital
Essex Holdings Limited	288,458,000	51.81
Ngiam Mia Je Patrick	297,374,667 <i>(note 1)</i>	53.41
Ngiam Mia Kiat Benjamin	295,449,667 <i>(note 2)</i>	53.07
Lauw Hui Kian	297,374,667 <i>(note 3)</i>	53.41

Notes:

1. (a) 2,250,000 shares were registered directly in the name of Ngiam Mia Je Patrick.
(b) 288,458,000 shares were held by Essex Holdings Limited (“Essex Holdings”) which is owned as to 50% by Ngiam Mia Je Patrick and as to 50% by Ngiam Mia Kiat Benjamin. Therefore, Ngiam Mia Je Patrick was deemed to be interested in these shares as he was entitled to exercise or control the exercise of more than one-third of the voting power of Essex Holdings at general meetings.
(c) 6,666,667 shares were held by Dynatech Ventures Pte Ltd (“Dynatech”) which is wholly owned by Essex Investment (Singapore) Pte Ltd (“Essex Singapore”). Since Essex Singapore is owned by Ngiam Mia Je Patrick and Ngiam Mia Kiat Benjamin in equal shares and therefore, Ngiam Mia Je Patrick was deemed to be interested in these shares as he was entitled to exercise or control the exercise of more than one-third of the voting power of Dynatech at general meetings.
2. (a) 325,000 shares were registered directly in the name of Ngiam Mia Kiat Benjamin.
(b) 288,458,000 shares were held by Essex Holdings; and
(c) 6,666,667 shares were held by Dynatech.
3. (a) Lauw Hui Kian is the spouse of Ngiam Mia Je Patrick (an executive Director). Lauw Hui Kian was deemed to be interested in the shares in which Ngiam Mia Je Patrick was interested. Ngiam Mia Je Patrick was interested in 297,374,667 shares of the Company.

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company : NIL

Financial year end date : 31st December

Registered address : Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

Head office and principal place of business : Room 2818, China Merchants Tower
Shun Tak Centre
168-200 Connaught Road Central
Hong Kong

Web-site address (if applicable) : www.essexbio.com

Share registrar : ***Principal share registrar:***
Butterfield Fulcrum Group (Cayman) Limited

Hong Kong share registrar:
Hong Kong Registrars Limited

Auditors : BDO Limited

B. Business activities

The Group specializes in biopharmaceutical drug development based on recombinant DNA technology. It is principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds and the research and development of biopharmaceutical products for the treatment of duodenal ulcers and nervous system damages and diseases, as well as other ophthalmic pharmaceutical projects.

In November 2005, Essex has expanded into another bio-technology related industry to further strengthen on the Group's core business. The Group has strategically acquired a 51% equity stake in 山東寶源生物有限公司 Baoyuan Bio-Agri (Shandong) Limited (“Baoyuan”) (formerly known as 煙台開發區寶源生物實業有限公司 Baoyuan Bio-Agri Technology (Yantai) Limited). Baoyuan was incorporated in Shandong, the PRC on 5th January, 2004 and commenced its business in June 2004. It is principally engaged in the research, development and production of organic and chemical formulated agricultural fertilisers, in solid and liquid forms, for the agriculture industry in the PRC.

C. Ordinary shares

Number of ordinary shares in issue : 556,750,000

Par value of ordinary shares in issue : HK\$0.10 each

Board lot size (in number of shares) : 4,000 Shares

Name of other stock exchange(s)
on which ordinary shares
are also listed : N/A

D. Warrants

Stock code : N/A

Board lot size : N/A

Expiry date : N/A

Exercise price : N/A

Conversion ratio : N/A
*(Not applicable if the warrant
is denominated in dollar value
of conversion right)*

No. of warrants outstanding : N/A

No. of shares falling to be
issued upon the exercise of
outstanding warrants : N/A

E. Other securities : **NIL**

Responsibility statement

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:

Ngiam Mia Je Patrick

Fung Chi Ying

Fang Haizhou

Mauffrey Benoit Jean Marie

Zhong Sheng

Yeow Mee Mooi